We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PSIX:NASDAQPower Solutions International, Inc. Analysis

Data as of 2026-06-26 - not real-time

$38.71

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Power Solutions International (PSIX) is trading at $38.71, well above its DCF-derived fair value of $8.55, indicating a significant overvaluation despite a low trailing PE of 8.7 versus an industry average of 32. Technicals point to a bearish backdrop – the 20‑day SMA sits at 39.67 and the 50‑day SMA at 52.96, both above the current price, while the 200‑day SMA remains at 69.27. Momentum is mixed: RSI is near 40 (oversold territory) and the MACD histogram is positive, suggesting short‑term bullish pressure, yet the overall trend is still bearish with decreasing volume and a high beta of 3.2 and 84% 30‑day volatility.
Fundamentally, PSIX posted revenue of $715.6 M (down 5.1% YoY) and net income of $102.2 M**, but its balance sheet is strained with a debt‑to‑equity ratio near 91% and negative free cash flow. The company offers no dividend, and while margins are modest (24% gross, 9% operating), the high ROE of 75% reflects a thin equity base rather than sustainable earnings power. Recent news highlights a sharp share‑price decline of 40% over the past month, underscoring heightened market skepticism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near support at $36.6 with limited upside to $43.2
  • Mixed technical signals (RSI low, MACD bullish histogram)
  • High volatility and beta increase short‑term risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Low PE vs industry suggests value appeal
  • Revenue contraction and high debt‑to‑equity raise concerns
  • Absence of dividend and negative free cash flow limit upside

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Overvaluation relative to DCF fair value
  • Sustained revenue decline and leverage risk
  • Cyclical industrial exposure and high beta amplify long‑term uncertainty

Key Metrics & Analysis

Financial Health

Revenue Growth-5.10%
Profit Margin14.28%
P/E Ratio8.7
ROE75.67%
ROA15.01%
Debt/Equity90.88
P/B Ratio4.8
Op. Cash Flow$34.4M
Free Cash Flow$-188000
Industry P/E32.0

Technical Analysis

TrendBearish
RSI39.9
Support$36.60
Resistance$43.23
MA 20$39.67
MA 50$52.96
MA 200$69.27
MACDBullish
VolumeDecreasing
Fear & Greed Index85.36

Valuation

Fair Value$8.55
Target Price$70.37
Upside/Downside81.78%
GradeOvervalued
TypeValue

Risk Assessment

Beta3.19
Volatility84.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.